Affinia Therapeutics
Rob has closed more than 50 strategic transactions across a broad range of R&D collaborations, licensing agreements, and mergers and acquisitions. Before Affinia Therapeutics, Rob was a Principal at the law firm Faber, Daeufer & Itrato PC, co-leading its R&D collaborations and licensing practice and working with prominent gene therapy clients. Prior to this, he was Vice President and Head of Business Strategy for GSK’s biotech partnering unit, and was Assistant General Counsel at GSK supporting Worldwide Business Development and R&D Operations. Earlier in his career, Rob held multiple roles including Biotech Patent Attorney at Akin, Gump, Strauss, Hauer, & Feld and Research Biochemist in Bioprocess R&D at Merck. Rob received his B.S. in Biochemistry from Albright College, M.S. in Biochemistry from Rutgers University and J.D. from Temple University.